Market Intelligence, Clinical Progress, and High-Purity Reagents for Solid Tumor & Resistance Indication Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for ABL2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ABL2 Mutant Recombinant Proteins High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. Theoretical MW. |
View ABL2 Products |
| Gene Delivery | ABL2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View ABL2 Products |
| Benchmark Ab | Anti-ABL2 Recombinant Antibody Sequence-verified reference clone for assay calibration. |
View ABL2 Products |
| Validator | ABL2 siRNA Set For knockdown verification. |
View ABL2 Products |
| Related Target A | ABL1 Paralog tyrosine kinase; compensatory resistance mechanism and selectivity counter-screen. |
View ABL1 Products |
| Related Target B | SRC Co-operating non-receptor tyrosine kinase; shared metastatic signaling axis. |
View SRC Products |
| Related Target C | BRAF Key node in bypass resistance pathways for solid tumors (e.g., melanoma). |
View BRAF Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| ABL1/ABL2 Selectivity & Paralog Off-target Profiling | Human ABL1 & ABL2 Kinase Domains available with >95% purity; Sequence Verified for orthogonal biochemical screening. |
| Resistance Mutation Surveillance | Custom mutant panel (Gatekeeper & Activation-Loop analogs); HEK293 expressed; Endotoxin Controlled. |
| Lack of Cellular Assay Controls | ABL2 Lentiviral Particles for stable phospho-assay cell lines; Full-length ORF with native folding. |
| False Positives / Target Engagement Validation | Validated ABL2 siRNA Set for knockdown confirmation; Reduce compound off-target noise. |
Live ABL2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ABL2 therapeutics is intensifying, with major players shifting focus from traditional pan-ABL inhibitors to next-generation selective modalities. Unlike its homolog ABL1, which is linked to leukemias via BCR-ABL1 fusion, ABL2 (ARG) plays a critical, distinct role in regulating the cytoskeleton, driving solid tumor metastasis, and mediating resistance to other targeted therapies (such as BRAF inhibitors in melanoma). As first-generation ABL1/ABL2 dual inhibitors mature in hematology, the next wave of R&D is targeting ABL2-selective suppression in solid tumor metastasis, allosteric regulation, and targeted protein degradation (PROTAC) to overcome acquired resistance mutations and off-target kinome toxicities.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Type I/II Kinase Inhibitor | Novartis, BMS, Oncology Biotechs | Metastatic Prostate & Breast Cancer, Leukemia | Selectivity Assay (Need ABL1 vs ABL2 WT & Mutant Proteins) |
| Allosteric Inhibitor | Academic Consortia & Pharma Pipelines | Refractory Solid Tumors | Full-length & Truncated Domain Binding (SPR/BLI) |
| Targeted Degrader (PROTAC) | Arvinas, Emerging Biotech Platforms | TKI-Resistant Metastasis, Melanoma | Cell-based Turnover Assay (Need Lentivirus Stable Lines) |
| Combination Therapy | Pfizer, AstraZeneca | Metastatic Breast Cancer, BRAF-mutant Melanoma | Pathway Validation (Need siRNA & Sequence Verified Controls) |